Company intelligence / Profile preview

Adamed Pharma

Ksawerów, Łódź, Polandadamed.com ↗

Ownership: Private
Employees: ~1800
Development stage: Commercial

Overview

Adamed has a broad commercial portfolio (~900 products/SKUs) across 19 therapeutic areas with global sales in over 70 countries. Its innovative pipeline includes small molecules and biologics targeting oncology and CNS indications. The company has successfully licensed out at least one CNS drug candidate and advanced several proprietary molecules to the clinical trial transfer stage.

Therapeutic areas: OncologyMetabolic DisordersPsychiatryCardiovascularInfectious Diseases
Modalities: Small moleculesrecombinant fusion proteinsgenerics
Industry: Biotech

Drug pipeline

5 assets

ADA-1101

Approved

4 more assets in the full pipeline.

Request access →

Partnerships

Ecupharma S.r.l. (Italy)Jagiellonian University consortiumMIT Enterprise Forum CEE partnervarious academic collaborations.

Beyond the preview

Go deeper on Adamed Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adamed Pharma.

Explore the full profile